Latest stories on ACRS
Leaked File Put Lenders in Bind Before Acrisure's Earnings Win
Bloomberg64 · neutralearnings
Aclaris Therapeutics Price Target Raised To 13 From 10 At Canaccord
The Fly64 · neutralanalyst
Aclaris Therapeutics, Inc. (ACRS) Discusses ATI-052 Proof-of-Concept Results in Atopic Dermatitis and Asthma - Slideshow
Seeking Alpha58 · neutralproduct/pr
ACRS Maintains by Wedbush -- Price Target Lowered to $8.00
GuruFocus38 · neutralanalyst
Aclaris Therapeutics price target lowered to $9 from $10 at Craig-Hallum
The Fly34 · bearishanalyst
ACRS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $16.00
GuruFocus52 · neutralanalyst
Aclaris Therapeutics, Inc. (ACRS) files 8-K
SEC 8-K53 · neutralgeneral
Aclaris Therapeutics, Inc. (ACRS) Discusses ATI-052 Proof-of-Concept Results in Atopic Dermatitis and Asthma Transcript
Seeking Alpha63 · neutralproduct/pr
Aclaris Reports Positive Asthma, Eczema Drug Trial Results — So, Why Is ACRS Stock Down Nearly 8%?
Stocktwits News34 · bearishgeneral
Aclaris Therapeutics prices 7.79M shares at $3.50 in public offering
The Fly22 · bearishgeneral
Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire26 · bearishgeneral
Aclaris Therapeutics’ ATI-052 shows efficacy in atopic dermatitis, asthma trial
The Fly64 · neutralproduct/pr
Aclaris Therapeutics, Inc. (ACRS) files 8-K
SEC 8-K50 · neutralgeneral
Arcus Shares Fall After Offering Priced
MarketWatch28 · bearishgeneral
Arcus Dips, But Recovers Steep Losses, On Merck-Rivaling News
Investors.com58 · neutralproduct/pr
Arcus stock tumbles 6% after unveiling casdatifan trial data
Investing.com Markets34 · bearishproduct/pr
Cantor Fitzgerald reiterates Aclaris Therapeutics stock rating
Investing.com Analyst Ratings50 · neutralanalyst
Aclaris Therapeutics management to meet virtually with Piper Sandler
The Fly56 · neutralgeneral
Cantor Fitzgerald reiterates Aclaris stock rating on LP opportunity
Investing.com Analyst Ratings50 · neutralanalyst
Cantor Fitzgerald reiterates Aclaris Therapeutics stock rating
Investing.com Analyst Ratings50 · neutralanalyst
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Business Insider56 · neutralgeneral
Canaccord initiates Aclaris stock with buy rating on pipeline potential
Investing.com Analyst Ratings61 · neutralanalyst
Canaccord starts Aclaris with Buy on ‘sizeable’ U.S. opportunities
The Fly61 · neutralanalyst
Aclaris Therapeutics initiated with a Buy at Canaccord
The Fly61 · neutralanalyst